We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+21.92%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.44B
AUM Growth
+$302M
Cap. Flow
+$9.92M
Cap. Flow %
0.69%
Top 10 Hldgs %
50.32%
Holding
229
New
57
Increased
37
Reduced
31
Closed
55
Avg Time Held Equity + Options
2.9 quarters
Top 10 Avg Time Held Equity + Options
4.7 quarters
Top 20 Avg Time Held Equity + Options
4.1 quarters
Avg Time Held Equity only
3.1 quarters
Top 10 Avg Time Held Equity only
4.7 quarters
Top 20 Avg Time Held Equity only
4.9 quarters

Top Buys

Rank Stock Value
1
NXTM
NxStage Medical Inc.
NXTM
+$24.7M
2
MDVN
MEDIVATION, INC.
MDVN
+$23.8M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$18.4M
4
STJ
St Jude Medical
STJ
+$16.6M
5
LJPC
La Jolla Pharmaceutical Company
LJPC
+$11.4M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$41.5M
2
HUM icon
Humana
HUM
+$20.1M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$12.4M
4
BAX icon
Baxter International
BAX
+$9.04M
5
XLRN
Acceleron Pharma
XLRN
+$6.5M

Sector Composition

Rank Sector Weight
1 Healthcare 78.68%
2 Miscellaneous 20.64%
3 Consumer Staples 0.52%
4 Consumer Discretionary 0.08%
5 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ARDX icon
76
Ardelyx
ARDX
$803M
$2.76M 0.19%
315,955
– –
2014 Q3
7 quarters
XENE icon
77
Xenon Pharmaceuticals
XENE
$3.35B
$2.55M 0.18%
432,800
+227,000
+110% +$1.56M
2014 Q4
6 quarters
RXDX
78
DELISTED
Ignyta, Inc.
RXDX
$2.36M 0.16%
435,260
-911,800
-68% -$6.07M
2015 Q2
4 quarters
IONS icon
79
PUT
Ionis Pharmaceuticals
IONS
$7.08B
$2.33M 0.16%
+100,000
New +$3.23M
2016 Q2
0 quarters
TARA icon
80
Protara Therapeutics
TARA
$160M
$2.21M 0.15%
6,875
– –
2014 Q4
6 quarters
MGCD
81
DELISTED
MGC Diagnostics Corporation
MGCD
$2.19M 0.15%
336,287
– –
2013 Q2
12 quarters
ADYX
82
DELISTED
Adynxx Inc
ADYX
$2.15M 0.15%
32,033
– –
2014 Q4
6 quarters
PGNX
83
PUT
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$2.11M 0.15%
+500,000
New +$2.41M
2016 Q2
0 quarters
EIGR
84
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$2.08M 0.14%
3,497
– –
2016 Q1
1 quarter
RLYP
85
PUT
DELISTED
RELYPSA INC COM
RLYP
$1.85M 0.13%
+100,000
New +$1.76M
2016 Q2
0 quarters
AFMD icon
86
DELISTED
Affimed
AFMD
$1.82M 0.13%
+73,430
New +$2.68M
2016 Q2
0 quarters
DSCI
87
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$1.71M 0.12%
432,884
– –
2014 Q1
9 quarters
GNMX icon
88
DELISTED
Aevi Genomic Medicine Inc
GNMX
$1.67M 0.12%
+300,000
New +$1.58M
2016 Q2
0 quarters
PETX
89
DELISTED
Aratana Therapeutics, Inc.
PETX
$1.62M 0.11%
256,500
-35,300
-12% -$227K
2016 Q1
1 quarter
ABMD
90
DELISTED
Abiomed Inc
ABMD
$1.61M 0.11%
14,700
+5,000
+52% +$497K
2016 Q1
1 quarter
CBPO
91
DELISTED
China Biologic Products Holdings, Inc.
CBPO
$1.49M 0.1%
14,000
– –
2016 Q1
1 quarter
VCEL icon
92
Vericel Corp
VCEL
$2.06B
$1.25M 0.09%
557,342
-689,970
-55% -$1.99M
2014 Q3
7 quarters
GMED icon
93
Globus Medical
GMED
$10.2B
$1.19M 0.08%
+50,000
New +$1.2M
2016 Q2
0 quarters
ABEOW icon
94
DELISTED
Abeona Therapeutics Inc Warrant
ABEOW
$1.07M 0.07%
1,259,636
– –
2015 Q2
4 quarters
BCLI icon
95
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$964K 0.07%
26,667
– –
2016 Q1
1 quarter
LPCN icon
96
CALL
Lipocine
LPCN
$13.4M
$912K 0.06%
+17,647
New +$2.73M
2016 Q2
0 quarters
LPCN icon
97
PUT
Lipocine
LPCN
$13.4M
$865K 0.06%
+16,729
New +$2.59M
2016 Q2
0 quarters
PZRX
98
DELISTED
PhaseRx, Inc.
PZRX
$852K 0.06%
+200,000
New +$988K
2016 Q2
0 quarters
CSBR icon
99
Champions Oncology
CSBR
$67.2M
$801K 0.06%
372,597
– –
2015 Q3
3 quarters
LXRX icon
100
Lexicon Pharmaceuticals
LXRX
$725M
$718K 0.05%
+50,000
New +$678K
2016 Q2
0 quarters
2 3
4
5 6

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q2 2016 Portfolio in Review

As of Q2 2016, Perceptive Advisors held 229 positions worth $1.44B, up 27% from $1.14B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors's Q2 2016 filing shows 57 new, 37 increased, 31 reduced and 55 closed positions. Its largest new stake was NxStage Medical Inc.: 1,382,410 shares worth $30M. The largest sale was Allergan plc, an estimated $41.5M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 93% a quarter earlier, followed by Miscellaneous and Consumer Staples.

  • Perceptive Advisors's largest Q2 2016 buy was NxStage Medical Inc.: 1,382,410 shares worth $30M.
  • Perceptive Advisors added most to MEDIVATION, INC. in Q2 2016, an estimated $23.8M increase.
  • Perceptive Advisors's biggest Q2 2016 reduction was Five Prime Therapeutics, Inc., cutting an estimated $12.4M.
  • Perceptive Advisors fully exited Allergan plc in Q2 2016, selling an estimated $41.5M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $1.44B portfolio in Q2 2016.
  • Perceptive Advisors opened 57 new positions and closed 55 in Q2 2016.
  • Perceptive Advisors's portfolio value rose 27% quarter-over-quarter to $1.44B.

Based on Perceptive Advisors's 13F filing for Q2 2016, filed 11 Aug 2016.